|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus-defining adequate administration methods显示文摘AIM To carry out randomized trial for evaluating effects of autologous bone marrow derived stem cell therapy(ABMSCT) through different routes.METHODS Bone marrow aspirate was taken from the iliac crest of patients. Bone marrow mononuclear cells were separatedand purified using centrifugation. These cells were then infused in a total of 21 patients comprising three groups of 7 patients each. Cells were infused into the superior pancreaticoduodenal artery(Group Ⅰ), splenic artery(Group Ⅱ) and through the peripheral intravenous route(Group Ⅲ). Another group of 7 patients acted as controls and a sham procedure was carried out on them(Group Ⅳ). The cells were labelled with the PET tracer F18-FDG to see their homing and in vivo distribution. Data for clinical outcome was expressed as mean ± SE. All other data was expressed as mean ± SD. Baseline and post treatment data was compared at the end of six months, using paired t-test. Cases and controls data were analyzed using independent t-test. A probability(P) value of < 0.05 was regarded as statistically significant. Measures of clinical outcome were taken as the change or improvement in the following parameters:(1) C-peptide assay;(2) HOMA-IR and HOMA-B;(3) reduction in Insulin dose; subjects who showed reduction of insulin requirement of more than 50% from baseline requirement were regarded as responders; and(4) reduction in HbA 1c. RESULTS All the patients, after being advised for healthy lifestyle changes, were evaluated at periodical intervals and at the end of 6 mo. The changes in body weight, body mass index, waist circumference and percentage of body fat in all groups were not significantly different at the end of this period. The results of intra-group comparison before and after ABMSCT at the end of six months duration was as follows:(1) the area under C-peptide response curve was increased at the end of 6 mo however the difference remained statistically non-significant(P values for fasting C-peptide were 0.973, 0.103, 0.263 and 0.287 respectively and the P values for stimulated C-peptide were 0.989, 0.395, 0.325 and 0.408 respectively for groups Ⅰ?to Ⅳ);(2) the Insulin sensitivity indices of HOMA IR and HOMA B also did not show any significant differences(P values for HOMA IR were 0.368, 0.223, 0.918 and 0.895 respectively and P values for HOMA B were 0.183, 0.664, 0.206 and 0.618 respectively for groups Ⅰto Ⅳ);(3) Group Ⅰshowed a significant reduction in Insulin dose requirement(P < 0.01). Group Ⅱ patients also achieved a significant reduction in Insulin dosages(P = 0.01). The Group Ⅰand Group Ⅱ patients together constituted the targeted group wherein the feeding arteries to pancreas were used for infusing stem cells. Group Ⅲ, which was the intravenous group, showed a non-significant reduction in Insulin dose requirement(P = 0.137). Group Ⅳ patients which comprised the control arm also showed a significant reduction in Insulin dosages at the end of six months(P < 0.05); and(4) there was a non-significant change in the Hb A1 c levels at the end of 6 mo across all groups(P = 0.355, P = 0.351, P = 0.999 and P = 0.408 respectively for groups Ⅰto Ⅳ). CONCLUSION Targeted route showed a significant reduction in Insulin requirement at the end of six months of study period whereas the intravenous group failed to show reduction. | Vikas Sood Anil Bhansali Bhagwant Rai Mittal Baljinder Singh Neelam Marwaha Ashish Jain Niranjan Khandelwal | 2017 | World Journal of Diabetes2017，8，7： | 6 |
| 2 | Technological Evolution and Radical Innovation 显示文摘 | ASHiSH SOOD GERARD J TELLIS G J | 2005 | Journal of Marketing2005，69，1： | 1 |
| 3 | Technological evolution and radical innovation 显示文摘 | Ashish Sood Gerald J Tell is | 2005 | Journal of Marketing2005，，69： | 1 |
| 4 | Technological Evolution and Radical Innovation显示文摘 | Ashish Sood Gerard Jellis | 2005 | Journal of Marketing2005，69，3： | 1 |
| 5 | Technological Evolu- tion and Radical Innovation 显示文摘 | ASHISH SOOD GERARD J TELLIS | 2005 | Journal of Marketing2005，69，3： | 1 |
| 6 | Targeting the A chilles’ heel of adult living donor liver transplant: Corner‐sparing sutures with mucosal eversion technique of biliary anastomosis显示文摘 | Vivek Vij Kausar Makki Vishal Kumar Chorasiya Gaurav Sood Ashish Singhal Puneet Dargan | 2016 | Liver Transpl2016，，1： | 1 |
| 7 | Impact of Living Donor Liver Transplantation on COVID-19 Clinical Outcomes from a Quaternary Care Centre in Delhi显示文摘Background and Aims:The anticipated fear of serious out-comes in coronavirus infected liver transplant recipients led to disruption of transplant services globally.The aim of our study was to analyze COVID-19 severity in transplant recipients and to compare the difference of COVID-19 clinical outcomes in early(<1 year)vs.late(>1 year)post-transplant period.Methods:41 post-living donor liver transplant recipients with COVID-19 infection were studied retrospectively from 1st April 2020 to 28th February 2021.Results:The median age was 49.00 years with a male preponderance(80.49%).Fif-teen patients had infection within 1 year of transplant and 26 were infected after 1 year of transplant.The overall median interval between transplantation and COVID-19 diagnosis was 816.00 days.Fever and malaise were the common presenting symptoms.The most common associated comorbidities were diabetes mellitus(65.85%)and hypertension(46.34%).The severity of illness was mild in 28(68.29%),moderate in 4(9.76%),severe in 6(14.63%)and critical in 3(7.32%).To identify associated risk factors,we divided our patients into less severe and more severe groups.Except for lymphopenia,there was no worsening of total bilirubin,transaminases,al-kaline phosphatase,and gamma-glutamyl transferase in the more severe group.Eight(19.51%)patients required inten-sive care unit admission and three(7.32%)died,while none suffered graft rejection.In recipients with early vs.late post-transplant COVID-19 infection,there were similar outcomes in terms of severity of COVID-19 illness,intensive care unit care need,requirement of respiratory support,and death.Conclusion:Living donor liver transplantation can be per-formed during the COVID-19 pandemic without the fear of poor recipient outcome in cases of unfortunate contraction of severe acute respiratory syndrome coronavirus-2. | Imtiakum Jamir Niteen Kumar Gaurav Sood Ashish George Pankaj Lohia Samba Siva Rao Pasupuleti Amrish Sahney Manav Wadhawan Ajay Kumar Abhideep Chaudhary | 2022 | Journal of Clinical and Translational Hepatology2022，10，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员